{
  "id": 5399444,
  "title": "Dramatic Improvement in Dermatomyositis Skin Symptoms With First Approved Oral Agent",
  "url": "https://urgent.news/2026/09/03/dramatic-improvement-in-dermatomyositis-skin-symptoms-with-first",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-03T18:10:24.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/dermatology/generaldermatology/122879"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- Patients with previously treated dermatomyositis had significant improvement in skin-related symptoms and quality of life when treated with the selective TYK2/JAK1 inhibitor brepocitinib (Lisraya), data from a randomized trial...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}